Catalyst Biosciences, Inc. entered into an Asset Purchase Agreement with GC Biopharma Corp. for the sale of its rare bleeding disorder program for $6 million in cash.
AI Assistant
GYRE THERAPEUTICS INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.